G
Giovanni Cappello
Researcher at University of Turin
Publications - 20
Citations - 530
Giovanni Cappello is an academic researcher from University of Turin. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 6, co-authored 15 publications receiving 143 citations.
Papers
More filters
Journal ArticleDOI
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Giulia Siravegna,Luca Lazzari,Giovanni Crisafulli,Andrea Sartore-Bianchi,Benedetta Mussolin,Andrea Cassingena,Cosimo Martino,Richard B. Lanman,Rebecca J. Nagy,Stephen R. Fairclough,Giuseppe Rospo,Giorgio Corti,Alice Bartolini,Pamela Arcella,Monica Montone,Francesca Lodi,Annalisa Lorenzato,Alice Vanzati,Emanuele Valtorta,Giovanni Cappello,Andrea Bertotti,Sara Lonardi,Vittorina Zagonel,Francesco Leone,Mariangela Russo,Antonella Balsamo,Mauro Truini,Federica Di Nicolantonio,Alessio Amatu,Erica Bonazzina,Silvia Ghezzi,Daniele Regge,Angelo Vanzulli,Livio Trusolino,Salvatore Siena,Silvia Marsoni,Alberto Bardelli +36 more
TL;DR: Genomic and functional analyses on samples and cell models from eight metastases of a patient co-recruited to a postmortem study unveiled lesion-specific evolutionary trees and pharmacologic vulnerabilities.
Journal ArticleDOI
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
Andrea Sartore-Bianchi,Sara Lonardi,Cosimo Martino,Elisabetta Fenocchio,Federica Tosi,Silvia Ghezzi,Francesco Leone,Francesca Bergamo,Vittorina Zagonel,Fortunato Ciardiello,Andrea Ardizzoni,Alessio Amatu,Katia Bencardino,Emanuele Valtorta,Elena Grassi,Valter Torri,Emanuela Bonoldi,Anna Sapino,Angelo Vanzulli,Daniele Regge,Giovanni Cappello,Alberto Bardelli,Livio Trusolino,Silvia Marsoni,Salvatore Siena +24 more
TL;DR: Based on high disease control, PFS similar to other anti-HER2 regimens, and low toxicity, pertuzumab in combination with T-DM1 can be considered for HER2+mCRC as a potential therapeutic resource.
Journal ArticleDOI
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.
Andrea Sartore-Bianchi,Filippo Pietrantonio,Sara Lonardi,Benedetta Mussolin,Francesco Rua,Elisabetta Fenocchio,Alessio Amatu,Salvatore Corallo,Chiara Manai,Federica Tosi,Paolo Manca,Francesca Daniel,Valter Torri,Angelo Vanzulli,Giovanni Cappello,Caterina Marchiò,Anna Sapino,Silvia Marsoni,Salvatore Siena,Alberto Bardelli +19 more
TL;DR: This data indicates that within RAS status therapeutic actionability remains confined to the limited subgroups of ERBB2 amphetamine-like substances in metastatic colorectal cancer.
Journal ArticleDOI
Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline – Update 2020
Cristiano Spada,Cesare Hassan,Davide Bellini,David Burling,Giovanni Cappello,Cristina Carretero,Evelien Dekker,Rami Eliakim,Margriet C. de Haan,Michal F. Kaminski,Anastasios Koulaouzidis,Andrea Laghi,Philippe Lefere,Thomas Mang,SM Milluzzo,Martina M. Morrin,Deirdre McNamara,Emanuele Neri,Silvia Pecere,Mathieu Pioche,Andrew Plumb,Emanuele Rondonotti,Manon C.W. Spaander,Stuart Taylor,Ignacio Fernandez-Urien,Jeanin E. van Hooft,Jaap Stoker,Daniele Regge +27 more
TL;DR: This is an update of the 2014–15 Guideline of the European Society of Gastrointestinal Endoscopy (ESGE) and the European society of gastrointestinal and Abdominal Radiology (ESGAR), which recommends computed tomographic colonography (CTC) as the radiological examination of choice for the diagnosis of colorectal neoplasia.
Journal ArticleDOI
Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer
Federica Tosi,Andrea Sartore-Bianchi,Sara Lonardi,Alessio Amatu,Francesco Leone,Silvia Ghezzi,Cosimo Martino,Katia Bencardino,Erica Bonazzina,Francesca Bergamo,Elisabetta Fenocchio,Erika Martinelli,Teresa Troiani,Giulia Siravegna,Gianluca Mauri,Valter Torri,Giovanna Marrapese,Emanuele Valtorta,Andrea Cassingena,Giovanni Cappello,Emanuela Bonoldi,Angelo Vanzulli,Daniele Regge,Fortunato Ciardiello,Vittorina Zagonel,Alberto Bardelli,Livio Trusolino,Silvia Marsoni,Salvatore Siena +28 more
TL;DR: Long-term follow-up analysis of HERACLES-A supports using of trastuzumab and lapatinib as treatment reference for KRAS wild-type, chemorefractory HER2-positive mCRC, and prolongation of survival is accompanied by CNS recurrences that will require diagnostic and therapeutic attention in future studies.